Karyopharm Therapeutics Inc (KPTI)

Etorro trading 970x250
Karyopharm Therapeutics Inc (KPTI) Logo

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of low-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory DLBCL. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration agreement with Curadev Pharma Pvt Ltd to identify and co-develop novel small molecules against various biological targets for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. Address: 85 Wells Avenue, Newton, MA, United States, 02459

Karyopharm Therapeutics Inc News and around…

Latest news about Karyopharm Therapeutics Inc (KPTI) common stock and company :

15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors
23 Oct, 2021 Yahoo! Finance

In this article, we will take a look at 15 biotech and pharmaceutical stocks to buy according to Palo Alto Investors. You can skip our detailed analysis of the fund’s history, investment strategy, and hedge fund performance, and go directly to the 5 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors. Palo […]

Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome
21 Oct, 2021 Yahoo! Finance

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the Phase 2 expansion of an ongoing open-label Phase 1/2 study investigating eltanexor, a novel oral, Selective Inhibitor of Nuclear Export (SINE) compound, as a single-agent or in combination with approved and investigational agents in patients with several types of hematologic and solid tumor cancers (KCP-8602-801; NCT02649790).

Interesting KPTI Put And Call Options For December 17th
15 Oct, 2021 FinancialContent

Investors in Karyopharm Therapeutics Inc (KPTI) saw new options begin trading this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KPTI options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

What 4 Analyst Ratings Have To Say About Karyopharm Therapeutics
12 Oct, 2021 FinancialContent

Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter: ...

Implied XBI Analyst Target Price: $214
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $214.39 per unit.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Oct, 2021 Yahoo! Finance

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 147,300 shares of Karyopharm's common stock to 21 newly-hired employees, with a grant date of September 30, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Sep, 2021 FinancialContent

Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The ...

Karyopharm Announces Upcoming Virtual Investor Conference Participation
07 Sep, 2021 Yahoo! Finance

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate in the following virtual investor conferences in September:

Interesting KPTI Call Options For October 15th
23 Aug, 2021 FinancialContent

Investors in Karyopharm Therapeutics Inc (KPTI) saw new options begin trading this week, for the October 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KPTI options chain for the new October 15th contracts and identified the following call contract of particular interest.

Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options
20 Aug, 2021 Yahoo! Finance

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
16 Aug, 2021 FinancialContent

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap ...

Karyopharm Therapeutics Charts Are Bearish With a Capital B
13 Aug, 2021 Yahoo! Finance

In this daily bar chart of KPTI, below, we can see that prices have been under selling pressure since February. The On-Balance-Volume (OBV) line is at a new low for the move down, and the Moving Average Convergence Divergence (MACD) oscillator is bearish. In this long-term weekly Japanese candlestick chart of KPTI, below, we can see that the stock has been under pressure for a long time and prices are down at a critical level.

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Cramer Shares His Thoughts On Moderna, Nvidia And More
13 Aug, 2021 FinancialContent

On CNBC's "Mad Money Lightning Round," Jim Cramer said Karyopharm Therapeutics Inc (NASDAQ: KPTI) is nothing ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Analysts Just Made A Major Revision To Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Revenue Forecasts
07 Aug, 2021 Yahoo! Finance

One thing we could say about the analysts on Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) - they aren't optimistic...

Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021
06 Aug, 2021 FinancialContent

Upgrades According to Wolfe Research, the prior rating for The AES Corp (NYSE:AES) was changed from Peer Perform to ...

10 Biggest Price Target Changes For Friday
06 Aug, 2021 FinancialContent

Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in ...

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

99 Biggest Movers From Yesterday
06 Aug, 2021 FinancialContent

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn ...

Karyopharm Therapeutics inc (KPTI) Q2 2021 Earnings Call Transcript
06 Aug, 2021 FinancialContent

KPTI earnings call for the period ending July 31, 2021.

12 Health Care Stocks Moving In Thursday's Intraday Session
05 Aug, 2021 FinancialContent

Gainers Nautilus Biotechnology (NASDAQ:NAUT) stock rose 25.23% to $9.38 during Thursday's regular session. Nautilus ...

Stocks That Hit 52-Week Lows On Thursday
05 Aug, 2021 FinancialContent

During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
05 Aug, 2021 FinancialContent

Gainers Ensysce Biosciences (NASDAQ:ENSC) shares rose 42.78% to $5.84 during Thursday's pre-market session. The ...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
05 Aug, 2021 Yahoo! Finance

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter ended June 30, 2021.

Karyopharm Therapeutics Inc (KPTI) is a NASDAQ Common Stock listed in , ,

970x250